HOT NEWS
Three scientists to receive Novartis prizes for immunology » The Novartis Prizes for Immunology are awarded to three scientists for their groundbreaking research...
Abbott announces CE Mark for world's longest coronary drug eluting stent » Abbott today announced CE Mark in Europe for the XIENCE Xpedition™ 48 Everolimus Eluting Coronary ...
Bayer HealthCare joins forces with Stroke Alliance for Europe » Ahead of the "Move for Health Day" (10 May) and the "European Stroke Day" (14 May), the Stroke Allia...
Sanofi strengthens its French-German partnership » Sanofi (EURONEXT: SAN and NYSE: SNY) announced its involvement in two major Franco-German projects ...
Merck Serono to finance the launch of the EspeRare Foundation » Merck Serono, a division of Merck, Darmstadt, Germany, today announced the launch of the EspeRare Fo...
Bayer HealthCare to broaden strategic alliance with German Cancer Research Cente... » Bayer HealthCare (Bayer) and the German Cancer Research Center (DKFZ) will extend their successful s...
AstraZeneca and Karolinska Institutet to create Integrated Translational Researc... » AstraZeneca and the Swedish medical university Karolinska Institutet announced today their intention...
Innovative cervical screening app launches in UK and Ireland » The new Roche cobas® HPV Test app for iPad, which provides essential information about cervical can...
Roche obtains EU approval for PERJETA, a new personalised treatment for aggressi... » Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Medicines Agency (EMA) has appr...
Novartis receives EU approval for Ilaris® in patients suffering acute gouty art... » Novartis announced that the European Commission (EC) has approved llaris (canakinumab, ACZ885) in th...
Nycomed
NycomedNycomed is a Takeda company since end of September 2011. Takeda is a research-based global company with its main focus on pharmaceuticals. The combined company has an active commercial presence in the therapeutic areas of metabolic diseases, gastroenterology, oncology, cardiovascular health, CNS diseases, inflammatory and immune disorders, respiratory diseases and pain management.

Takeda's traditional strengths in North America, Japan, and the rest of Asia, are now complemented by Nycomed's position in Europe and the high growth emerging markets. The combined company has a presence in more than 70 countries worldwide, and ranked 12th by global Rx sales, 14th in the BRIC countries and 18th in Europe. For more information visit www.nycomed.com.

Nycomed RSS Channel
Title Filter     Display # 
# Article Title Hits
1 Takeda Appoints Jostein Davidsen Head of Emerging Markets 5355
2 Nycomed reports double-digit growth across emerging markets in second quarter 2011 6257
3 Nycomed continues to outperform in emerging markets in first quarter 2011 7513
4 Takeda to Acquire Nycomed - Transaction will Transform Takeda's Global Business 7900
5 Nycomed well positioned in emerging markets 9427
6 Nycomed Announces Agreement with Eurand for ZENPEP® in Russia-CIS 9173
7 Daxas® (Roflumilast) included as a new treatment option in latest international COPD guidelines 12811
8 Nycomed is keeping the pace in third quarter 2010 9808
9 Global market launch of Daxas® (Roflumilast) kicks off in Germany 12463
10 Nycomed's Daxas® (roflumilast) receives marketing authorisation in the European Union 12831
11 Nycomed's first quarter 2010 results confirm the direction 6735
12 Nycomed's novel anti-inflammatory therapy Daxas® (roflumilast) recommended for approval in the European Union 7508
13 Nycomed on track in 2009 with strong growth in Key Products 5097
14 Nycomed sustains commitment to Russia-CIS and invests in new pharmaceutical production plant 6159
15 Nycomed reports sustained momentum in second quarter 2009 3754
16 Nycomed to acquire local portfolio from Sanofi-Aventis and Zentiva 4648
17 Nycomed's Instanyl® is first intranasal fentanyl approved in Europe 6395
18 Nycomed receives Marketing Authorization for Pantoprazole 20mg OTC from European Commission 7757
19 Nycomed Reports a Solid Start to 2009 2675
20 Nycomed files European marketing authorisation application for Daxas® 3165
 
  • «
  •  Start 
  •  Prev 
  •  1 
  •  2 
  •  Next 
  •  End 
  • »
Page 1 of 2